JP2002510622A5 - - Google Patents

Download PDF

Info

Publication number
JP2002510622A5
JP2002510622A5 JP2000541995A JP2000541995A JP2002510622A5 JP 2002510622 A5 JP2002510622 A5 JP 2002510622A5 JP 2000541995 A JP2000541995 A JP 2000541995A JP 2000541995 A JP2000541995 A JP 2000541995A JP 2002510622 A5 JP2002510622 A5 JP 2002510622A5
Authority
JP
Japan
Prior art keywords
group
alkyl
groups
polysubstituted
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000541995A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002510622A (ja
JP5253696B2 (ja
Filing date
Publication date
Priority claimed from DE19814838A external-priority patent/DE19814838C2/de
Application filed filed Critical
Publication of JP2002510622A publication Critical patent/JP2002510622A/ja
Publication of JP2002510622A5 publication Critical patent/JP2002510622A5/ja
Application granted granted Critical
Publication of JP5253696B2 publication Critical patent/JP5253696B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000541995A 1998-04-02 1999-03-22 抗腫瘍作用を有するインドリル−3−グリオキシル酸誘導体 Expired - Fee Related JP5253696B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19814838A DE19814838C2 (de) 1998-04-02 1998-04-02 Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
DE19814838.0 1998-04-02
PCT/EP1999/001918 WO1999051224A1 (de) 1998-04-02 1999-03-22 Indolyl-3-glyoxylsäure-derivate mit antitumorwirkung

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011053448A Division JP2011148809A (ja) 1998-04-02 2011-03-10 抗腫瘍作用を有するインドリル−3−グリオキシル酸誘導体

Publications (3)

Publication Number Publication Date
JP2002510622A JP2002510622A (ja) 2002-04-09
JP2002510622A5 true JP2002510622A5 (enExample) 2011-05-19
JP5253696B2 JP5253696B2 (ja) 2013-07-31

Family

ID=7863398

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000541995A Expired - Fee Related JP5253696B2 (ja) 1998-04-02 1999-03-22 抗腫瘍作用を有するインドリル−3−グリオキシル酸誘導体
JP2011053448A Pending JP2011148809A (ja) 1998-04-02 2011-03-10 抗腫瘍作用を有するインドリル−3−グリオキシル酸誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011053448A Pending JP2011148809A (ja) 1998-04-02 2011-03-10 抗腫瘍作用を有するインドリル−3−グリオキシル酸誘導体

Country Status (32)

Country Link
US (4) US6232327B1 (enExample)
EP (1) EP1071420B1 (enExample)
JP (2) JP5253696B2 (enExample)
KR (1) KR100583545B1 (enExample)
CN (1) CN1148183C (enExample)
AR (1) AR018175A1 (enExample)
AT (1) ATE304352T1 (enExample)
AU (1) AU768510B2 (enExample)
BG (1) BG64838B1 (enExample)
BR (1) BR9909902A (enExample)
CA (1) CA2326833C (enExample)
DE (2) DE19814838C2 (enExample)
DK (1) DK1071420T3 (enExample)
EE (1) EE04354B1 (enExample)
ES (1) ES2249884T3 (enExample)
GE (1) GEP20032967B (enExample)
HR (1) HRP20000643A2 (enExample)
HU (1) HUP0101530A3 (enExample)
ID (1) ID26504A (enExample)
IL (2) IL138737A0 (enExample)
IS (1) IS2307B (enExample)
NO (1) NO327721B1 (enExample)
NZ (1) NZ507084A (enExample)
PL (1) PL192779B1 (enExample)
RS (1) RS49866B (enExample)
RU (1) RU2262339C2 (enExample)
SK (1) SK286393B6 (enExample)
TR (1) TR200002853T2 (enExample)
TW (1) TWI230608B (enExample)
UA (1) UA70942C2 (enExample)
WO (1) WO1999051224A1 (enExample)
ZA (1) ZA200006150B (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814838C2 (de) * 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
DE19946301A1 (de) 1998-04-02 2001-04-19 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit therapeutisch wertvollen Eigenschaften
AU4834200A (en) * 1999-05-10 2000-11-21 Protarga, Inc. Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof
AU777725B2 (en) * 1999-09-17 2004-10-28 Baylor University Indole-containing and combretastatin-related anti-mitotic and anti-tubulin polymerization agents
US6849656B1 (en) 1999-09-17 2005-02-01 Baylor University Indole-containing and combretastatin-related anti-mitotic and anti-tubulin polymerization agents
TWI269654B (en) * 1999-09-28 2007-01-01 Baxter Healthcare Sa N-substituted indole-3-glyoxylamide compounds having anti-tumor action
KR20070053362A (ko) * 1999-11-23 2007-05-23 메틸진, 인크. 히스톤 디아세틸라제의 억제제
GB9928696D0 (en) 1999-12-03 2000-02-02 Swan Thomas & Co Ltd Optical devices and methods of manufacture thereof
IT1315267B1 (it) 1999-12-23 2003-02-03 Novuspharma Spa Derivati di 2-(1h-indol-3-il)-2-oxo-acetammidi ad attivita'antitumorale
DE19962300A1 (de) * 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
IT1318641B1 (it) * 2000-07-25 2003-08-27 Novuspharma Spa Ammidi di acidi 2-(1h-indol-3-il)-2-oxo-acetici ad attivita'antitumorale.
DE10037310A1 (de) 2000-07-28 2002-02-07 Asta Medica Ag Neue Indolderivate und deren Verwendung als Arzneimittel
JP2005504790A (ja) 2001-09-13 2005-02-17 シンタ ファーマスーティカルズ コーポレイション 癌を治療するための3−グリオキシリルアミドインドール
TWI323658B (en) 2001-12-06 2010-04-21 Nat Health Research Institutes Novel compounds of indol-3-yl-2-oxyacetylamide derivatives, pharmaceutical composition thereof, and method for manufacturing the same
US7109227B2 (en) 2002-08-26 2006-09-19 National Health Research Institutes Imidazolamino compounds
CA2509222A1 (en) * 2002-12-10 2004-06-24 Wyeth Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
DE10318609A1 (de) * 2003-04-24 2004-11-11 Elbion Ag 5-Hydroxyindole mit N-Oxidgruppen und deren Verwendung als Therapeutika
DE10318611A1 (de) * 2003-04-24 2004-11-11 Elbion Ag 4-, 6- oder 7-Hydroxyindole mit N-Oxidgruppen und deren Verwendung als Therapeutika
WO2004108702A1 (de) * 2003-06-05 2004-12-16 Zentaris Gmbh Indolderivate mit apoptose induzierender wirkung
US7205299B2 (en) * 2003-06-05 2007-04-17 Zentaris Gmbh Indole derivatives having an apoptosis-inducing effect
EP1484329A1 (de) * 2003-06-06 2004-12-08 Zentaris GmbH Indolderivate mit Apoptose induzierender Wirkung
US20050075364A1 (en) * 2003-07-01 2005-04-07 Kap-Sun Yeung Indole, azaindole and related heterocyclic N-substituted piperazine derivatives
US7211588B2 (en) * 2003-07-25 2007-05-01 Zentaris Gmbh N-substituted indolyl-3-glyoxylamides, their use as medicaments and process for their preparation
EP1670787B1 (en) 2003-09-11 2012-05-30 iTherX Pharma, Inc. Cytokine inhibitors
US20050124623A1 (en) 2003-11-26 2005-06-09 Bender John A. Diazaindole-dicarbonyl-piperazinyl antiviral agents
DE102004031538A1 (de) * 2004-06-29 2006-02-09 Baxter International Inc., Deerfield Pharmazeutische Darreichungsform zur oralen Verabreichung eines schwerlöslichen Wirkstoffs, Verfahren zu deren Herstellung und Kit
WO2006002887A1 (en) * 2004-06-29 2006-01-12 Baxter International Inc. Aqueous drink solution of indibulin (d-24851) and an organic acid
AU2005304952B2 (en) * 2004-11-08 2013-04-04 Baxter Healthcare S.A. Nanoparticulate compositions of tubulin inhibitors
US20060100209A1 (en) * 2004-11-09 2006-05-11 Chong-Hui Gu Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US20060100432A1 (en) * 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
ES2644450T3 (es) 2004-12-31 2017-11-29 Dr. Reddy's Laboratories Ltd. Nuevos derivados de bencilamina como inhibidores de CETP
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
WO2006099256A2 (en) * 2005-03-11 2006-09-21 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US20060280787A1 (en) * 2005-06-14 2006-12-14 Baxter International Inc. Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
US7598380B2 (en) * 2005-08-03 2009-10-06 Bristol-Myers Squibb Company Method of preparation of azaindole derivatives
WO2007044560A2 (en) * 2005-10-06 2007-04-19 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US7851476B2 (en) * 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7807671B2 (en) 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
MX2009001327A (es) * 2006-08-07 2009-06-05 Ironwood Pharmaceuticals Inc Compuestos de indol.
WO2008066807A1 (en) * 2006-11-28 2008-06-05 Ziopharm Oncology, Inc. Use of indolyl-3-glyoxylic acid derivatives including indibulin, alone or in combination with further agents for treating cancer
EP1964835A1 (en) * 2007-02-28 2008-09-03 Centre National de la Recherche Scientifique Derivatives of psammaplin A, a method for their synthesis and their use for the prevention or treatment of cancer
CN101085779A (zh) * 2007-07-11 2007-12-12 中国人民武装警察部队医学院 取代吲哚-3-基草酰表鬼臼毒素衍生物及其盐及其用途
GB0715103D0 (en) * 2007-08-03 2007-09-12 Lectus Therapeutics Ltd Calcium ion channel modulators and uses thereof
GB0909441D0 (en) * 2009-06-02 2009-07-15 Univ Sheffield Novel indole derivatives
US9585810B2 (en) 2010-10-14 2017-03-07 Fresenius Medical Care Holdings, Inc. Systems and methods for delivery of peritoneal dialysis (PD) solutions with integrated inter-chamber diffuser
AR084433A1 (es) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc Inhibidores de la faah y composiciones farmaceuticas que los contienen
WO2012154967A1 (en) 2011-05-12 2012-11-15 Proteostasis Therapeutics, Inc. Proteostasis regulators
US9199967B2 (en) 2011-08-18 2015-12-01 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors
EP2760864B1 (en) 2011-09-27 2018-01-24 Dr. Reddy's Laboratories Ltd. 5-BENZYLAMINOMETHYL-6-AMINOPYRAZOLO[3,4-b]PYRIDINE DERIVATIVES AS CHOLESTERYL ESTER-TRANSFER PROTEIN (CETP) INHIBITORS USEFUL FOR THE TREATMENT OF ATHEROSCLEROSIS
CN102942516B (zh) * 2012-11-05 2015-02-25 宁波大学 一种生物碱类化合物及其制备方法和应用
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
CA2905509A1 (en) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Hsp90-targeted cardiac imaging and therapy
IL225540A (en) * 2013-04-02 2015-09-24 Igal Nir A method, system, and software for automatically generating a speech database for speech recognition
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
CN105198788A (zh) * 2015-09-30 2015-12-30 蒋军荣 一种吲哚氧代乙酰(n-二芳甲基)哌嗪衍生物及其制备方法和应用
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
WO2018209239A1 (en) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
US12030888B2 (en) 2021-02-24 2024-07-09 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1028812A (en) * 1962-08-28 1966-05-11 Ici Ltd Indole derivatives
GB1089071A (en) * 1964-02-28 1967-11-01 Merck & Co Inc Indole derivatives
FR2182915A1 (en) * 1972-03-30 1973-12-14 Nelson Res & Dev Substd indoles, benzimidazoles - as anti-immune agents , antitumour agents, serotonin inhibitors, hypnotics
AU671865B2 (en) * 1992-10-20 1996-09-12 Toray Industries, Inc. Eosinophil infiltration inhibitor
US5405864A (en) * 1993-10-15 1995-04-11 Syntex (U.S.A.) Inc. Chemotherapeutic maleimides
IL113210A (en) * 1994-04-01 2001-01-28 Lilly Co Eli 1H-indole-3- glyoxylamide spla2 inhibitors and pharmaceutical compositions containing them
EP0747380B1 (en) * 1995-06-07 1998-09-30 Eli Lilly And Company Compounds and compositions with nitrogen-containing non-basic side chains
DE19636150A1 (de) * 1996-09-06 1998-03-12 Asta Medica Ag N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
US6262044B1 (en) * 1998-03-12 2001-07-17 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPASES)
US6225329B1 (en) * 1998-03-12 2001-05-01 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPases)
HUP0102612A2 (hu) 1998-03-12 2001-11-28 Novo Nordisk A/S Fehérje-tirozinfoszfatázokat moduláló vegyületek és ezeket tartalmazó gyógyászati készítmények
DE19814838C2 (de) * 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
DE19946301A1 (de) * 1998-04-02 2001-04-19 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit therapeutisch wertvollen Eigenschaften
ES2262072T3 (es) 1998-04-28 2006-11-16 Elbion Ag Derivados de indol y su utilizacion como inhibidores de la fosfodiesterasa 4.
JP2000239252A (ja) 1999-02-16 2000-09-05 Mitsubishi Chemicals Corp インドール誘導体
AU4834200A (en) 1999-05-10 2000-11-21 Protarga, Inc. Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof
DE19962300A1 (de) * 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
US7205299B2 (en) 2003-06-05 2007-04-17 Zentaris Gmbh Indole derivatives having an apoptosis-inducing effect
DE102004031538A1 (de) 2004-06-29 2006-02-09 Baxter International Inc., Deerfield Pharmazeutische Darreichungsform zur oralen Verabreichung eines schwerlöslichen Wirkstoffs, Verfahren zu deren Herstellung und Kit
US20060280787A1 (en) 2005-06-14 2006-12-14 Baxter International Inc. Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof

Similar Documents

Publication Publication Date Title
JP2002510622A5 (enExample)
NO996316L (no) Faktor Xa-inhibitorer med en noeytral P1-spesifisitetsgruppe
WO2001062705A3 (en) Aminoalcohol derivatives
AU4327600A (en) Aryl sulfonyls as factor xa inhibitors
WO2003055441A3 (en) Medicaments
CA2408602A1 (en) Phenylglycine derivatives
WO2003035668A3 (en) Novel anti-inflammatory androstane derivatives -17-carboxy-lactone substituted steroids with an aryl-carboxylic ester in position 17.alpha
DK1526132T3 (da) Substituerede oxazolidinoner og deres anvendelse som faktor Xa-hæmmer
TR200100432T2 (tr) Hepatit C inhibitörü tri-peptidler
DE50015330D1 (de) Herstellung von n-substituierten 2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamiden
ATE269312T1 (de) N-(amidinophenyl)-n'-(subst.)-3h-2,4- benzodiazepin-3-on derivative als faktor xa inhibitoren
AP9901442A0 (en) 4-(2-Keto-1-benzimidazolinyl) piperidine compounds as orl1-receptor agonists.
CO4770975A1 (es) Derivados de quinazolina sustituidos
HUP0401729A2 (hu) IV típusú foszfodiészteráz inhibitor hatású alkin-aril-naftiridin-4(1H)-on-származékok és ezeket tartalmazó gyógyszerkészítmények
CA2206754A1 (en) Benzimidazole derivatives with antihistaminic activity
DE60039238D1 (de) C-2-modifizierte erythromycinderivate
EP1741428A3 (en) Cell adhesion inhibitors
SE0004245D0 (sv) Novel compounds and their use
CA2203237A1 (en) Aminotetrazole derivatives useful as nitric oxide synthase inhibitors
TR200100700T2 (tr) EtO2C--CH2-(R)Cgl-Aze-Pab-OH'nin kristalin formları
AU2001286768A1 (en) Novel macrocycles and uses thereof
NO20026095L (no) Kumarinderivater med COMT inhiberende aktivitet
SE9904765D0 (sv) Pharmaceutically-useful compounds
CA2412596A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
NO981393D0 (no) Guanidinoproteasehemmere